Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Updated Results and Correlative Analysis: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)

Sairah Ahmed, Ian W. Flinn, Matthew Mei, Peter A. Riedell, Philippe Armand, Natalie S. Grover, Renu Balyan, Cliff Ding, Aung Myo, Ivan D. Horak, Helen E. Heslop

Blood (2022) 140 (Supplement 1): 7496–7497.

https://doi.org/10.1182/blood-2022-158869

Published: 2022

Journal Articles

Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)

David M. Kurtz, Sairah Ahmed, Cheuk Ka Tong, Matthew Mei, Cliff Ding, Ian W. Flinn, Peter A. Riedell, Gregory J. Hogan, Andre Schultz, Jacob J. Chabon, Helen E. Heslop, Aung Myo, Ash A. Alizadeh, Ivan D. Horak

Blood (2022) 140 (Supplement 1): 2378–2380.

https://doi.org/10.1182/blood-2022-162150

Published: 2022

Journal Articles

Phase 1b/2 Study of Autologous CD30.CAR-T Cells in Combination with Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma after Failure of Frontline Therapy (ACTION)

Matthew Mei, Sairah Ahmed, Amer Beitinjaneh, Natalie S. Grover, Carlos A. Ramos, Khong Bee Kang, Paul I. Nadler, Aung Myo, Ivan D. Horak, Helen E. Heslop

Blood (2022) 140 (Supplement 1): 12728–12730.

https://doi.org/10.1182/blood-2022-157131

Published: 2022

Journal Articles

Safety and Efficacy Profile of Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)

Sairah Ahmed, Ian W. Flinn, Matthew Mei, Peter A. Riedell, Philippe Armand, Natalie S Grover, Andreas Engert, Natalia Lapteva, Paul I. Nadler, Aung Myo, Helen E. Heslop

Blood (2021) 138 (Supplement 1): 3847.

https://doi.org/10.1182/blood-2021-146100

Published: 2021